Kidney Week 2025: Exhibitor Spotlight Schedule
Thursday, November 6 - Saturday, November 8
George R. Brown Convention Center, Exhibit Hall D
Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in three theaters on the exhibit hall floor. Seating is limited and available on a first-come, first-served basis to fully registered Kidney Week participants only. Exhibitor Spotlights are not CE (continuing education) activities.
The 10:00 a.m. presentations include breakfast. All other presentations include lunch.
Thursday, November 6
10:00-10:45 a.m.
HighVolumeHDF: The Next Standard of Care for US Patients - Evidence and Practical Use
Presented by Fresenius Medical Care
11:00-11:45 a.m.
Global Pathways to Home: Strategies for Success
Presented by Vantive Healthcare
11:30 a.m.-12:15 p.m.
Expert Perspectives and Patient Experiences: Upgrading to a Stronger Foundation in IgA Nephropathy
Presented by Travere Therapeutics
12:00-12:45 p.m.
Advancing Care in Lupus Nephritis: Exploring the Evolving Landscape
Presented by Genentech
12:30-1:15 p.m.
Houston, We Have a Solution: Integrating Genetics into Clinical Practice
Presented by Natera
1:00-1:45 p.m.
B-cell Modulation in IgA Nephropathy
Presented by Otsuka
Friday, November 7
10:00-10:45 a.m.
Decoding a Silent Threat: Aldosterone's Impact on Hypertension and Cardiovascular and Renal Morbidity
Presented by AstraZeneca
11:00-11:45 a.m.
Expanding Perspectives in Hyperphosphatemia Treatment; A Different Approach
Presented by Ardelyx, Inc.
11:30 a.m.-12:15 p.m.
IgA Nephropathy Paradigm Shift: KDIGO Guidelines and the Centrality of B Cells
Presented by Vertex Pharmaceuticals
12:00-12:45 p.m.
Hypoxia-Inducible Factor Activation & Erythropoietic Effects in Anemia due to CKD
Presented by Akebia Therapeutics
12:30-1:15 p.m.
Navigating the Crossroads of IgAN: 2 Distinct Paths to Reducing Proteinuria
Presented by Novartis Pharmaceuticals
1:00-1:45 p.m.
Targeting IgAN Early: Considerations for Adding Potentially Disease Modifying Therapy to Frontline Treatment
Presented by Calliditas Therapeutics
Saturday, November 8
10:00-10:45 a.m.
Optimizing Transitions of Care in Kidney Transplantation: The Role of Envarsus XR®
Presented by Veloxis Pharmaceuticals, Inc.
11:00-11:45 a.m.
Jardiance® (empagliflozin) tablets: Expert Perspectives on Clinical Trial Data and Approved Indications
Presented by Boehringer Ingelheim/Lilly USA
11:30 a.m.-12:15 p.m.
Taking a Different Direction in the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Presented by Novo Nordisk
12:00-12:45 p.m.
Role of CD38+ Cells in Immune-Mediated Kidney Disease
Presented by Biogen
12:30-1:15 p.m.
Translating KDIGO Guidelines into Therapeutic Goals in IgA Nephropathy
Presented by Vera Therapeutics
1:00-1:45 p.m.
DefenCath® Indication, Use and Navigating Reimbursement Across Settings of Care
Presented by CorMedix
Additional information, if provided by the supporter, is available by clicking on the presentation title.